Cargando…

The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies

WHO-defined SARS-CoV-2 variants of concern (VOC) drive therapeutics and vaccine development. The Omicron VOC is dominating the arena since November 2021, but the number of its sublineages is growing in complexity. Omicron represent a galaxy with a myriad of stars that suddenly rise and expand before...

Descripción completa

Detalles Bibliográficos
Autores principales:	Focosi, Daniele, McConnell, Scott, Casadevall, Arturo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528072/ https://www.ncbi.nlm.nih.gov/pubmed/36260961 http://dx.doi.org/10.1016/j.drup.2022.100882

Ejemplares similares

Spike mutations in SARS-CoV-2 AY sublineages of the Delta variant of concern: implications for the future of the pandemic
por: Focosi, Daniele, et al.
Publicado: (2022)

Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge
por: Focosi, Daniele, et al.
Publicado: (2023)

Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review
por: Focosi, Daniele, et al.
Publicado: (2021)

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
por: Casadevall, Arturo, et al.
Publicado: (2023)

Monoclonal antibody therapies against SARS-CoV-2
por: Focosi, Daniele, et al.
Publicado: (2022)

Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy
por: Focosi, Daniele, et al.
Publicado: (2022)

Decoding the effects of spike receptor binding domain mutations on antibody escape abilities of omicron variants
por: Chakraborty, Sandipan, et al.
Publicado: (2022)

A Web Tool to Estimate Baseline Anti-Spike Monoclonal Antibody Efficacy Based on Regional Genomic Surveillance
por: Focosi, Daniele
Publicado: (2023)

Do We Really Need Omicron Spike-Based Updated COVID-19 Vaccines? Evidence and Pipeline
por: Focosi, Daniele, et al.
Publicado: (2022)

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
por: Focosi, Daniele, et al.
Publicado: (2022)

Spike protein evolution in the SARS-CoV-2 Delta variant of concern: a case series from Northern Lombardy
por: Baj, Andreina, et al.
Publicado: (2021)

Omicron variant evolution on vaccines and monoclonal antibodies
por: Sabbatucci, Michela, et al.
Publicado: (2023)

Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis
por: Focosi, Daniele, et al.
Publicado: (2022)

Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape
por: Zhao, Zhennan, et al.
Publicado: (2022)

Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein
por: Javanmardi, Kamyab, et al.
Publicado: (2022)

SARS-CoV-2 Omicron spike mediated immune escape and tropism shift
por: Gupta, Ravindra
Publicado: (2022)

Convergence of immune escape strategies highlights plasticity of SARS-CoV-2 spike
por: Yu, Xiaodi, et al.
Publicado: (2023)

A spike protein S2 antibody efficiently neutralizes the Omicron variant
por: Hu, Jia, et al.
Publicado: (2022)

Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies
por: Jary, Aude, et al.
Publicado: (2022)

Emergence of Genomic Diversity in the Spike Protein of the “Omicron” Variant
por: Basak, Surajit, et al.
Publicado: (2023)

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J, et al.
Publicado: (2022)

Omicron Variant Escapes Therapeutic Monoclonal Antibodies (mAbs) Including Recently Released Evusheld(®), Contrary to 8 Prior Main Variant of Concern (VOC)
por: Boschi, Céline, et al.
Publicado: (2022)

Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19
por: Focosi, Daniele, et al.
Publicado: (2021)

Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern
por: Morgan, Mahali S., et al.
Publicado: (2022)

Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron antibody
por: Yin, Wanchao, et al.
Publicado: (2022)

SARS-CoV-2 Spike Protein Mutations and Escape from Antibodies: A Computational Model of Epitope Loss in Variants of Concern
por: Triveri, Alice, et al.
Publicado: (2021)

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J., et al.
Publicado: (2022)

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
por: Weisblum, Yiska, et al.
Publicado: (2020)

SARS-CoV-2 variants, spike mutations and immune escape
por: Harvey, William T., et al.
Publicado: (2021)

Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant
por: Verkhivker, Gennady
Publicado: (2022)

The ongoing evolution of variants of concern and interest of SARS-CoV-2 in Brazil revealed by convergent indels in the amino (N)-terminal domain of the spike protein
por: Resende, Paola Cristina, et al.
Publicado: (2021)

Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern
por: Kovacech, Branislav, et al.
Publicado: (2022)

Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study
por: Nag, Anish, et al.
Publicado: (2022)

Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern
por: Shi, Juan, et al.
Publicado: (2022)

Omicron Spike Protein is Vulnerable to Reduction
por: Yao, Zhong, et al.
Publicado: (2023)

Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
por: Focosi, Daniele, et al.
Publicado: (2023)

Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies
por: Ding, Chengchao, et al.
Publicado: (2021)

Spike protein of SARS-CoV-2 Omicron variant: An in-silico study evaluating spike interactions and immune evasion
por: Jimenez Ruiz, Jose A., et al.
Publicado: (2022)

Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies
por: Laurini, Erik, et al.
Publicado: (2021)

Increased immune escape of the new SARS-CoV-2 variant of concern Omicron
por: Hu, Jie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ljv3cbmq0l671u0oubqqtujra8